Samsung Biologics is acquiring a Swiss peptide-focused contract development and manufacturing organization (CDMO) for 2.7 trillion Korean won, expanding its business from antibody-based drugs to peptides—a core material for obesity and diabetes treatments—to enter the rapidly growing obesity drug production market.
Samsung Bio announced on the 20th that it had signed a contract to acquire PolyPeptide Group for 1.46 billion Swiss francs (approximately 2.7 trillion Korean won). The company plans to secure 100% ownership through acquiring major shareholders’ stakes and a public tender offer, completing the acquisition by the end of this year. A company official stated, “This is the largest merger and acquisition (M&A) in South Korea’s pharmaceutical and biotech industry.”
Peptides are short-chain molecules composed of 2–50 amino acids, which constitute proteins. They transmit hormones or signals between cells in the body. Representative drugs synthesized artificially include GLP-1-based obesity and diabetes treatments such as Wegovy and Mounjaro. Recently, their application has expanded to anticancer agents, immune and rare disease treatments, and brain disorder therapies.
Founded in 1996, PolyPeptide Group is a specialized CDMO handling peptide drug candidate development from process optimization to commercial production. It has accumulated over 1,000 cases of development and production experience. The company operates six production and research facilities across Sweden, Belgium, France, the U.S., and India, employing approximately 1,500 people. Its primary business focuses on metabolic disease treatments, including GLP-1.
Through this acquisition, Samsung Bio will inherit production facilities, technology, skilled personnel, and PolyPeptide Group’s existing clients and orders. It has established a foundation to generate sales in the peptide business immediately after the acquisition. Leveraging production bases in the U.S., Europe, and India, it can also expand connections with global pharmaceutical companies.
Samsung Bio has previously expanded its business from antibody drugs to messenger ribonucleic acid (mRNA) and antibody-drug conjugates (ADCs). By adding peptides, it can now offer contract production for both antibody drugs and obesity treatment materials. The company plans to pursue cross-orders for pharmaceutical firms developing both antibody and peptide therapies simultaneously.
Peptide drugs require complex synthesis processes and precise management to remove impurities. Samsung Bio will combine its experience in constructing and operating large-scale antibody factories with PolyPeptide Group’s synthesis technology. It is also reviewing plans to expand local production facilities based on market demand.
Samsung Biologics CEO John Rim stated, “This is a strategic decision encompassing the three growth pillars of production capacity, business portfolio, and global presence. We will strengthen our competitiveness in the global CDMO market by integrating the capabilities of both companies.”
https://www.chosun.com/english/industry-en/2026/07/20/UGJ5QOMKTJBFBKVXTQE7U6D72U/

